SHANGHAI, November 12, 2024 /PRNewswire/ -- Yao Ming Kangde recently announced that the company received the highest score in the industry in the 2024 S&P Global Corporate Sustainability Assessment (CSA), ranking first in the global “life science tools and services” category [1].

“This assessment fully demonstrates Yao Ming Kangde's ability to continuously improve its ability to respond to environmental, social and governance (ESG) related risks and opportunities in global operations, and further proves the company's outstanding performance in ESG practices and its firm commitment to sustainable development,” said Mr. Hu Zhengguo, vice chairman and ESG chairman of Yao Ming Kangde. “We have always unswervingly embedded ESG concepts into the core strategy of the company's global operations and are working with industry colleagues to build a healthier and more sustainable future.”

CSA is the world's leading corporate sustainability assessment tool that quantifies the disclosure and performance of companies in the industry on economic, environmental and social standards. As a third-party independent and credible benchmark for the industry, CSA links an enterprise's sustainability performance to its business strategy, and fully reflects the company's sustainability management level.

In the 2024 CSA evaluation, Yao Ming Kangde received an excellent score of 80 points (out of 100), an increase of 11 points compared to 2023. At the same time, the company obtained a perfect score of 43 out of 102 assessment questions, including risk management, code of conduct, supplier evaluation and development, climate risk management, climate-related financial information disclosure, return on human capital investment, and occupational health and safety plans.

As an enabler of innovation, a trusted partner for customers, and a contributor to the global health industry, Yao Ming Kangde integrates ESG concepts into every aspect of the company's strategy and operations. In 2024, Yao Ming Kangde was rated ESG AA by MSCI for the fourth year in a row; in 2023 and 2024, the company was selected for 2 consecutive years in the S&P Global Sustainability Yearbook and FTSE Russell Social Responsibility Index series, and was also rated as a Sustainalytics “Highest Industry Rating” and “Regional Highest Rating” company; in 2024, the company joined the “United Nations Global Compact” (UNGC) and promised to support the ten principles of the Global Compact; 2023 The company joined the “Science Based Targets Initiative” (SBTi) to reduce carbon emissions. Yao Ming Kangde's outstanding ESG performance has also been highly recognized by global ESG rating agencies such as CDP and EcoVadis.

About Yakming Kangde

Pharmaceutical Kangde (stock code: 603259.SH/2359.HK) provides integrated, end-to-end new drug development and production services for the global pharmaceutical and life science industry, and has operating bases in Asia, Europe, North America, etc. Through its unique “CRDMO” and “CTDMO” business models, Pharmacovigant continuously lowers the R&D threshold, helps customers improve R&D efficiency, and brings more breakthrough treatment solutions to patients. The scope of services covers fields such as chemical drug development and production, biological research, pre-clinical testing and clinical trial research and development, and precision medicine research and development, testing and production. In 2024, Yao Ming Kangde was rated ESG (Environmental, Social and Governance) AA by MSCI for the fourth year in a row. Currently, the company's enabling platform is carrying R&D and innovation projects of more than 6,000 partners from more than 30 countries around the world. It is committed to bringing more new drugs and good medicines to patients around the world and realizing the vision of “making the world free of difficult drugs and diseases that are difficult to treat” as soon as possible.

[1] As of November 12, 2024